Stocks CVS Health Corp

More

  • You got the flu shot. But will it work this year? Monday, 19 Oct 2015 | 10:13 AM ET
    A woman receives a free flu shot from a Walgreens employee during a free flu shot clinic in Oakland, California.

    The market for influenza vaccines globally is estimated to be about $4 billion, and growing.

  • Pharmacy & Retail Stocks Top Trades to go Wednesday, 7 Oct 2015 | 2:15 PM ET

    The "Halftime Report" traders give their top trades of the show.

  • Express Scripts to cover pricy new cholesterol drugs Wednesday, 7 Oct 2015 | 6:46 AM ET
    Cholesterol in blood stream.

    The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol.

  • Lightning Round: Chart is terrible but it's a buy Tuesday, 6 Oct 2015 | 7:00 PM ET
    Mad Money Lightning Round

    Jim Cramer gives his opinion at rapid speed to caller stocks, including this health care play with a scary chart that is screaming to be bought.

  • Wal-Mart taking on Target in yet another category Tuesday, 6 Oct 2015 | 2:38 PM ET
    Walmart customers push carts past reusable shopping bags in Los Angeles.

    Wal-Mart on Tuesday announced a series of initiatives to beef up its health and wellness offerings.

  • Sept 30- Target Corp said it will match online prices of 29 of its rivals including Amazon.com and Wal-Mart Stores Inc, as the race to grab shoppers intensifies ahead of the holiday season. Other large retailers Target will price-match include Costco Wholsesale Corp, Best Buy, Macy's Inc and CVS Health Corp, the company said in a statement late on Tuesday.

  • BOSTON, Sept 24- Top U.S. heart doctors said on Thursday that newly developed cholesterol treatments that cost more than $14,000 per year are best used for the small group of patients for which they have been approved, at least for now. CVS Health, a pharmacy benefit manager, has set out a program that aims to limit the drug's use and has said that it would try to use...

  • How top money managers are playing rising rates Thursday, 17 Sep 2015 | 10:40 AM ET
    Traders work on the floor of the New York Stock Exchange.

    CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.

  • *Forecasts profit of $0.12- $0.19/ shr. Sept 17- Drugstore chain operator Rite Aid Corp cut its full-year forecasts for total earnings and drugstore sales, citing lower pharmacy reimbursements and expenses related to its $2 billion acquisition of pharmacy benefit manager EnvisionRx. Rite Aid shares fell nearly 9 percent in morning trading on Thursday.

  • Sept 16- CVS Health Corp reached a $48 million settlement of a lawsuit accusing the U.S. drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business, culminating in a plunge in its stock price. CVS bought Caremark in March 2007 and changed its name to CVS Health last September. In April 2014, CVS agreed to pay $20...

  • Sept 16- CVS Health Corp reached a $48 million settlement of a lawsuit accusing the U.S. drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business, culminating in a plunge in its stock price. The Woonsocket, Rhode Island- based company changed its name to CVS Health last September. In April 2014, CVS agreed to pay...

  • The stock niche that's posting double-digit returns Wednesday, 16 Sep 2015 | 9:02 AM ET
    Prescription drugs

    Prescription drug prices are out of control, but there's a way to make your money back: The drugstore stocks are very healthy right now.

  • Sept 11- Amgen Inc said on Friday it had asked the U.S. Food and Drug Administration to approve a monthly single-dosing option for its recently approved cholesterol drug, Repatha. At the time of approval, Amgen had said it planned to make the monthly dosing option available next year. Amgen's drug is being launched in Europe at around half the U.S. price.

  • The Boston- based Institute for Clinical and Economic Review said its analyses indicated "that the price that best represents the overall benefits" the drugs may provide patients would be between $3,615 and $4,811 a year, a 67 percent discount off the list prices. Praluent from Regeneron Pharmaceuticals and Sanofi has a U.S. price of $14,600 for a year of...

  • The Boston- based Institute for Clinical and Economic Review said its analyses indicated "that the price that best represents the overall benefits" the drugs may provide patients would be between $3,615 and $4,811 a year, a 67 percent discount off the list prices. Praluent from Regeneron Pharmaceuticals and Sanofi has a U.S. price of $14,600 for a year of...

  • CHICAGO, Sept 3- CVS Health Corp said on Thursday its decision to stop selling tobacco products last year led to a 1 percent decrease in cigarette sales in some states where the drugstore chain has a sizeable presence. The September 2014 decision hurt sales, with general merchandise revenue at CVS pharmacies open at least a year falling 7.8 percent in the second...

  • Top investor: Safe stocks for a crazy market Wednesday, 2 Sep 2015 | 10:21 AM ET
    Louis Navellier, CIO, Navellier & Associates.

    Louis Navellier, whose "Squawk Box" model portfolio is up 19% this year, shares his views on how to ride out the volatility in the market.

  • WASHINGTON, Aug 27- The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those at high risk of cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA. The drugs are expected to generate more than $2 billion a...

  • CVS signs telehealth deals to boost access to MDs Wednesday, 26 Aug 2015 | 4:51 PM ET
    MinuteClinic

    CVS customers in six states will get access to telehealth services starting in the fourth quarter.

  • BOSTON, Aug 25- Popular consumer brands Discovery Communications, Chipotle Mexican Grill and CVS Health Corp pay their chief executive officers more than a thousand times what they pay their typical worker, giving them the biggest internal pay gaps among S&P 500 companies, according to a study released on Tuesday. The research from job-hunting website...